$13.84
0.29%
Nasdaq, Sep 02, 10:01 pm CET
ISIN
KYG8807B1068
Symbol
TBPH

Theravance Biopharma Inc Stock price

$13.84
+2.62 23.35% 1M
+4.69 51.26% 6M
+4.43 47.08% YTD
+5.59 67.76% 1Y
+4.47 47.71% 3Y
-4.87 26.03% 5Y
-0.95 6.42% 10Y
-9.12 39.72% 20Y
Nasdaq, Closing price Tue, Sep 02 2025
-0.04 0.29%
ISIN
KYG8807B1068
Symbol
TBPH
Industry

Key metrics

Basic
Market capitalization
$697.0m
Enterprise Value
$389.8m
Net debt
positive
Cash
$338.8m
Shares outstanding
50.4m
Valuation (TTM | estimate)
P/E
55.4 | 14.7
P/S
9.0 | 6.1
EV/Sales
5.1 | 3.4
EV/FCF
1.6
P/B
3.1
Financial Health
Equity Ratio
49.6%
Return on Equity
-32.1%
ROCE
-9.6%
ROIC
-19.7%
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$77.2m | $114.8m
EBITDA
$-29.9m | -
EBIT
$-35.6m | $-26.2m
Net Income
$13.0m | $47.4m
Free Cash Flow
$244.8m
Growth (TTM | estimate)
Revenue
24.5% | 78.4%
EBITDA
14.9% | -
EBIT
8.6% | 38.2%
Net Income
128.5% | 184.1%
Free Cash Flow
2,649.8%
Margin (TTM | estimate)
Gross
-
EBITDA
-38.7% | -
EBIT
-46.2%
Net
16.9% | 41.3%
Free Cash Flow
317.1%
More
EPS
$0.3
FCF per Share
$4.9
Short interest
11.4%
Employees
97
Rev per Employee
$660.0k
Show more

Is Theravance Biopharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Theravance Biopharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Theravance Biopharma Inc forecast:

8x Buy
73%
3x Hold
27%

Analyst Opinions

11 Analysts have issued a Theravance Biopharma Inc forecast:

Buy
73%
Hold
27%

Financial data from Theravance Biopharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
77 77
24% 24%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 72 72
10% 10%
93%
- Research and Development Expense 41 41
14% 14%
53%
-30 -30
15% 15%
-39%
- Depreciation and Amortization 5.76 5.76
47% 47%
7%
EBIT (Operating Income) EBIT -36 -36
9% 9%
-46%
Net Profit 13 13
129% 129%
17%

In millions USD.

Don't miss a Thing! We will send you all news about Theravance Biopharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Theravance Biopharma Inc Stock News

Neutral
PRNewsWire
about 23 hours ago
DUBLIN , Sept. 2, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that management will participate at the H.C.
Neutral
PRNewsWire
9 days ago
Topline results anticipated in Q1 2026 and , if successful, planning for expedited NDA submission  If approved, ampreloxetine could address a critical unmet need as the first therapy with the potential to provide durable benefit for the 40,000 patients in the U.S. with symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA) Ampreloxetine has Orphan Dr...
Neutral
Seeking Alpha
21 days ago
Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q2 2025 Earnings Conference Call August 12, 2025 5:00 PM ET Company Participants Aine Miller - Senior VP of Development & Head of Ireland Office Aziz Sawaf - Senior VP & CFO Rhonda F. Farnum - Chief Business Officer and Senior VP of Commercial & Medical Affairs Rick E.
More Theravance Biopharma Inc News

Company Profile

Theravance Biopharma, Inc. operates as a biopharmaceutical company. It focuses on the discovery, research, development, and commercialization of organ-selective medicines. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.

Head office Cayman Islands
CEO Rick Winningham
Employees 97
Founded 2013
Website www.theravance.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today